β-blockers as initial therapy for hypertension

JAMA

Volumn 310, Issue 17, 2013, Pages 1851-1852

  Wiysonge, Charles S ^a   Opie, Lionel H ^b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; OXPRENOLOL; PLACEBO; PROPRANOLOL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DEPRESSION; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MONOTHERAPY; MORTALITY; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUAL DYSFUNCTION; SUDDEN DEATH;

EID: 84887071736     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.277510     Document Type: Note

References (6)

1. Opie LH. β-Blocking agents. In: Opie LH, Gersh BJ, eds. Drugs for the Heart. 8th ed. Philadelphia, PA: Elsevier Saunders; 2013:1-37.
2. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH. β-Blockers for hypertension. Cochrane Database Syst Rev. 2012;11:CD002003.
3. Mancia G, Fagard R, Narkiewicz K, et al Task Force Members. 2013 ESH/ESC guidelines for the management of arterial hypertension. J Hypertens. 2013;31(7):1281-1357.
4. Lewin A, Punzi H, Luo X, Stapff M. Nebivolol monotherapy for patients with systolic stage II hypertension. Clin Ther. 2013;35(2):142-152.
5. Vanhoutte PM, Gao Y. β-Blockers, nitric oxide, and cardiovascular disease. Curr Opin Pharmacol. 2013;13(2):265-273.
6. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289(19):2560-2572.